Novo Nordisk’s NovoRapid and Levemir found to significantly reduce severe hypoglycaemia
Novo Nordisk's short-acting and long-acting modern insulin analogues NovoRapid (insulin aspart) and Levemir (insulin detemir) have significantly reduced severe hypoglycaemia in people with type 1 diabetes compared to human insulin (regular/NPH), acco… (Source: Drug Development Technology)
Source: Drug Development Technology - May 6, 2014 Category: Pharmaceuticals Source Type: news
Insulin in Patients With Diabetes and Declining KidneysInsulin in Patients With Diabetes and Declining Kidneys
How does insulin glargine and insulin detemir dosing change with changing renal function? Therapeutic Advances in Endocrinology and Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Novo Nordisk increased operating profit by 32% in 2012 (31 January 2013)
Sales growth of 18% driven by Victoza®, NovoRapid® and
Levemir®
Sales increased by 18% to 78.0 billion in Danish kroner and by
12% in local currencies.
•Sales of modern insulins increased by 21% (15% in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2013 Category: Pharmaceuticals Source Type: news
Insulin Analogues Dosing and Costs -- Detemir vs GlargineInsulin Analogues Dosing and Costs -- Detemir vs Glargine
Which analog is more cost-effective? Insulin detemir or insulin glargine? BMC Endocrine Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 28, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Exenatide more effective than insulin detemir: study
NEW YORK (Reuters Health) - Exenatide is more effective than insulin detemir when added to oral
glucose-lowering therapies, European researchers say. (Source: Modern Medicine)
Source: Modern Medicine - January 9, 2013 Category: Journals (General) Source Type: news
Once-weekly exenatide versus once- or twice-daily insulin detemir in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
This study is the first to compare EQW and insulin detemir, with respect to glycaemic control, body weight, lipids, safety, tolerability, and patient-reported outcomes in patients with type 2 diabetes whose diabetes was inadequately controlled with metformin (with or without sulfonylureas). Patients were randomised to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma ... (Source: NeLM - News)
Source: NeLM - News - January 4, 2013 Category: Drugs & Pharmacology Source Type: news
